Operation Warp Speed Funds Potential Antibody Therapy for COVID-19

Regeneron Pharmaceuticals signed a $450 million deal with the United States via Operation Warp Speed—a program initiated by the federal government to speed up the development and implementation of vaccines and treatments for COVID-19—to fund the company’s antibody treatment. The cocktail, REGN-COV2, contains both laboratory-generated antibodies and those collected from patients who have recovered from the illness caused by the novel coronavirus. REGN-COV2 is under evaluation as a potential preventive agent and treatment for COVID-19. Regeneron hopes to have the cocktail ready by early fall. The federal government will own all of the doses developed, and plans to provide them to Americans free of charge. Read more here.